Cancer Drug Roundup

Restricted access

Now that positive results from Phase 3 clinical trials have been reported, the European Medicines Agency (EMA) has recommended approval for tivozanib through the EMA’s Committee for Medicinal Products for Human Use (CHMP), as treatment for advanced renal cell carcinoma (RCC). The drug, brand named Fotivda (AVEO Pharmaceuticals, Cambridge, MA) could receive a final decision for approval by late August or early September 2017. The US Food and Drug Administration approved the drug in 2013.

EUSA Pharma, a specialty pharmaceutical company based in Hemel Hempstead, UK, that has a distribution network in approximately 40 countries around the world, is poised